1. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate;Eslami;Calcif Tissue Int,2011
2. Bisphosphonate-induced osteopetrosis;Whyte;N Engl J Med,2003
3. Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. Sept 9, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagmentAdvisoryCommittee/UCM270958.pdf.
4. Unites States District Court for the Southern District of New York sworn testimony Dr. Thomas Bold Senior Director of Clinical Risk Management and Safety Surveillance March 3, 2009, MDL#1789.
5. US National Library of Medicine and National Institutes of Health. PubMed. http://www.ncbi.nlm.nih.gov/pubmed/ [accessed 06.09.12].